Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry.

MLA

Lazaro Salvador, Maria, et al. “Portopulmonary Hypertension: Prognosis and Management in the Current Treatment Era – Results from the REHAP Registry.” Internal Medicine Journal, vol. 51, no. 3, Mar. 2021, pp. 355–65. EBSCOhost, https://doi.org/10.1111/imj.14751.

APA

Lazaro Salvador, M., Quezada Loaiza, C. A., Rodríguez Padial, L., Barberá, J. A., López, M. M., López, R. R., Sala, L. E., Alcolea, S., Blanco, I., & Escribano, S. P. (2021). Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry. Internal Medicine Journal, 51(3), 355–365. https://doi.org/10.1111/imj.14751

Chicago

Lazaro Salvador, Maria, Carlos A. Quezada Loaiza, Luis Rodríguez Padial, Joan A. Barberá, Meseguer, Manuel López, Reyes, Raquel López, Llinas, Ernest Sala, Sergio Alcolea, Isabel Blanco, and Subías, Pilar Escribano. 2021. “Portopulmonary Hypertension: Prognosis and Management in the Current Treatment Era – Results from the REHAP Registry.” Internal Medicine Journal 51 (3): 355–65. doi:10.1111/imj.14751.